Table 2.
Multivariate Analyses of Positive Blood Cultures With Associated CLABSI Diagnosis and Blood Culture Contamination
| Covariate | CLABSI Diagnosis, OR (95% CI) |
P Value | Covariate | Blood-Culture Contamination, OR (95% CI) |
P
Value |
|---|---|---|---|---|---|
| COVID-19 diagnosis | 6.94 (1.78–27.10) | .005 | COVID-19 diagnosis | 2.78 (1.19–6.50) | .019 |
| Sex | Sex | .901 | |||
| Male | 1.00 (ref) | Male | 1.00 (ref) | ||
| Female | 0.75 (0.21–2.66) | .658 | Female | 1.05 (0.51–2.16) | |
| Age | 0.96 (0.93–0.99) | .014 | Age | 1.01 (0.99–1.03) | .303 |
| Race | Race | ||||
| White | 1.00 (ref) | White | 1.00 (ref) | ||
| Black | 0.86 (0.09–8.19) | .894 | Black | 3.21 (1.04–9.88) | .042 |
| Hispanic | 4.50 (0.22–90.30) | .326 | Hispanic | 3.32 (0.57–19.49) | .184 |
| Other | 1.94 (0.24–15.21) | .527 | Other | 1.30 (0.47–3.62) | .614 |
| Comorbidities | Comorbidities | ||||
| Malignancy | 5.54 (1.02–30.05) | .047 | Diabetes | 1.51 (0.70–3.22) | .292 |
| Hypertension | 0.40 (0.06–2.80) | .354 | Asthma | 0.63 (0.06–6.58) | .697 |
| Diabetes | 0.65 (0.09–4.94) | .681 | CKD | 2.07 (0.81–5.22) | .125 |
| ESRD | 4.77 (1.37–16.60) | .014 | |||
| CAD | 0.46 (0.17–1.23) | .124 | |||
| Stroke | 0.28 (0.02–3.19) | .304 | |||
| Hypertension | 0.54 (0.24–1.19) | .124 | |||
| Obesity | 4.06 (1.79–9.17) | .001 | |||
| Malignancy | 0.94 (0.34–2.55) | .905 | |||
| Organ transplant | 0.40 (0.05–3.28) | .395 | |||
| Immunotherapy | 0.71 (0.08–6.34) | .756 | |||
| ≥2 cultures | 0.57 (0.43–0.74) | <.0001 |
Note. OR, odds ratio; CI, confidence interval; CAD, coronary artery disease; CI, confidence interval; CKD, chronic kidney disease; CLABSI, central-line–associated bloodstream infection; ESRD, end-stage renal disease.